Transcriptional Regulation in Neurodegeneration

Transcriptional dysregulation is a fundamental pathological feature of neurodegenerative diseases, affecting the expression of genes critical for protein homeostasis, mitochondrial function, synaptic plasticity, neuronal survival, and cellular stress responses. The complex interplay between transcription factors, epigenetic modifiers, and RNA polymerase II machinery becomes disrupted in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other disorders.

Gene Regulation Diagram

flowchart TD
    A["Transcription Factor"]  -->  B["DNA Binding"]
    B  -->  C["Gene Activation"]
    C  -->  D["mRNA Production"]
    D  -->  E["Protein Synthesis"]

    A  -->  F["Chromatin Remodeling"]
    F  -->  B

    E  -->  G["Cellular Function"]
    D  -->  H["Post-transcriptional Regulation"]

    style A fill:#1a0a1f,stroke:#333
    style G fill:#0e2e10,stroke:#333

Overview

Gene expression control in neurons involves multiple layers of regulation:

• Transcription factors: DNA-binding proteins that activate or repress gene expression

• Epigenetic modifiers: Histone modifications and DNA methylation

• Chromatin remodeling: ATP-dependent chromatin restructuring

• Non-coding RNAs: miRNAs and lncRNAs that modulate transcription

Key Transcription Factors in Neurodegeneration

NF-κB (Nuclear Factor Kappa-B)

The master regulator of inflammatory responses^{1Epigenetics in AD (2015)2015 · DOI 10.1038/nrn3720Open reference}:

NRF2 (Nuclear Factor Erythroid 2-Related Factor 2)

Central coordinator of antioxidant responses:

• Regulates ARE-containing genes

• Controls glutathione synthesis

• Protects against oxidative stress

• Dysregulated in AD, PD, ALS

PGC-1α (PPARG Coactivator 1 Alpha)

Master regulator of mitochondrial biogenesis:

• Coordinates mitochondrial gene expression

• Regulates TFAM, NRF1, NRF2

• Protects dopaminergic neurons

• Reduced in PD substantia nigra

REST (RE1-Silencing Transcription Factor)

Neuronal survival factor:

• Represses pro-apoptotic genes

• Protects against oxidative stress

• Lost in AD and MCI

• Therapeutic target

FOXO Transcription Factors

Stress-responsive transcriptional regulators:

• Activate autophagy genes

• Promote neuronal survival

• Regulated by insulin/IGF-1 signaling

• Impaired in metabolic diseases

Disease-Specific Transcriptional Changes

Alzheimer’s Disease

Key transcription factors:

• BACE1 upregulation

• APP promoter activation

• Synaptic gene repression (REST loss)

Parkinson’s Disease

• TH (tyrosine hydroxylase) downregulation

• DJ-1 promoter methylation

• PGC-1α reduction in substantia nigra

• Alpha-synuclein transcriptional control

Amyotrophic Lateral Sclerosis

• Broad transcriptional alterations

• TDP-43 pathology affects RNA processing

• FUS mutations disrupt transcription

• Astroglial transcriptional changes

Huntington’s Disease

• Mutant HTT acts as transcription factor dysregulator

• REST nuclear localization异常

• PGC-1α downregulation

• Mitochondrial gene suppression

Epigenetic Mechanisms

DNA Methylation

• Global hypomethylation in AD

• Gene-specific hypermethylation

• Age-related methylation changes

• Environmental factor effects

Histone Modifications

Chromatin Remodeling

• SWI/SNF complex dysfunction

• Nucleosome positioning alterations

• Transcriptional accessibility changes

Therapeutic Targeting

Small Molecule Approaches

• HDAC inhibitors: Valproic acid, sodium butyrate

• BET inhibitors: JQ1, IBET151

• NF-κB inhibitors: Pyrrolidine dithiocarbamate

• NRF2 activators: Sulforaphane, bardoxolone

Gene Therapy

• REST overexpression

• PGC-1α activation

• NRF2 stabilization

Epigenetic Drugs

• DNA methyltransferase inhibitors

• Histone deacetylase inhibitors

• Histone demethylase modulators

Biomarkers

• Blood DNA methylation patterns

• Histone modification signatures

• Peripheral monocyte transcriptional profiles

See Also

• Neuroinflammation Pathway

• Mitochondrial Dysfunction

• Epigenetic Regulation

• Synaptic Dysfunction

• Protein Homeostasis

Epigenetic Mechanisms in Transcriptional Regulation

Histone Modifications in Neurodegeneration

Histone modifications play a crucial role in transcriptional regulation in neurodegenerative diseases:

Histone Acetylation

Histone acetylation relaxes chromatin structure and promotes gene expression:

• HDAC (histone deacetylase) inhibitors show therapeutic potential in AD and PD

• Class I HDACs (HDAC1, 2, 3) are primarily nuclear

• Class II HDACs (HDAC4, 5, 6) shuttle between nucleus and cytoplasm

• HDAC6 is a major target in neurodegenerative diseases due to its role in tau and α-synuclein aggregation^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}

Histone Methylation

Histone methylation can activate or repress transcription depending on the residue:

• H3K4me3: Active promoter mark, reduced in AD

• H3K9me3: Heterochromatin mark, altered in aging

• H3K27me3: Repressive mark, dysregulated in neurodegeneration

• H3K9me3 and H3K27me3 changes are associated with transcriptional silencing of neuroprotective genes^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}

Histone Ubiquitination

Histone H2A and H2B ubiquitination contribute to transcriptional regulation:

• H2A ubiquitination is involved in X-chromosome inactivation and gene silencing

• H2B ubiquitination regulates transcriptional elongation

• Dysregulation of histone ubiquitination is observed in AD and PD^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}

DNA Methylation in Neurodegeneration

DNA methylation patterns are altered in neurodegenerative diseases:

Global Hypomethylation

• Global DNA hypomethylation is observed in AD brain

• Hypomethylation of specific genes (e.g., SNCA in PD) contributes to disease

• Aging is associated with global DNA hypomethylation^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}

Gene-Specific Hypermethylation

• The promoter of the BDNF gene is hypermethylated in AD

• GADD45B promoter hypermethylation affects DNA repair

• LINE-1 retrotransposons become demethylated with age^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}

Chromatin Remodeling Complexes

ATP-dependent chromatin remodeling complexes regulate nucleosome positioning:

SWI/SNF Complex

The SWI/SNF complex remodels chromatin for transcription:

• BRG1 (SMARCA4) is essential for neuronal differentiation

• Mutations in SWI/SNF components are linked to neurodevelopmental disorders

• Altered SWI/SNF function is observed in AD^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}

NuRD Complex

The NuRD complex combines ATP-dependent remodeling with histone deacetylation:

• MTA1, MTA2, and MTA3 are components

• HDAC1 and HDAPI are recruited

• NuRD is involved in transcriptional repression of neuronal genes^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}

Non-Coding RNAs in Transcriptional Regulation

MicroRNAs (miRNAs)

miRNAs regulate gene expression post-transcriptionally:

Key miRNAs in Alzheimer’s Disease

• miR-9: Regulates BDNF and REST

• miR-124: Involved in neuronal differentiation

• miR-146a: Regulates complement factor H

• miR-155: Pro-inflammatory miRNA

Key miRNAs in Parkinson’s Disease

• miR-7: Targets α-synuclein

• miR-153: Targets LRRK2

• miR-124: Protects dopaminergic neurons

• miR-29 family: Targets APP and BACE1^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}

Long Non-Coding RNAs (lncRNAs)

lncRNAs regulate transcription through various mechanisms:

NEAT1

NEAT1 forms nuclear paraspeckles:

• Upregulated in AD and ALS

• Involved in stress response

• Regulates gene expression through paraspeckle formation^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}

MALAT1

MALAT1 regulates alternative splicing:

• Highly expressed in neurons

• Dysregulated in AD

• Regulates synaptic plasticity^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}0

HOTAIR

HOTAIR regulates HOX gene expression:

• Upregulated in AD

• Recruits PRC2 for gene silencing

• Associated with cognitive decline^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}1

Transcriptional Dysregulation in Specific Diseases

Amyotrophic Lateral Sclerosis (ALS)

Transcriptional changes in ALS include:

• Downregulation of mitochondrial genes

• Upregulation of stress response genes

• Dysregulation of RNA metabolism genes

• Alterations in neurotrophic factor expression

C9orf72 expansion affects transcription through:

• RNA foci formation sequestering RNA-binding proteins

• Translation of dipeptide repeats

• Epigenetic dysregulation^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}2

Frontotemporal Dementia (FTD)

FTD shows characteristic transcriptional changes:

• Tau pathology affects transcriptional regulators

• GRN (progranulin) mutations affect histone acetylation

• C9orf72 expansion causes similar changes to ALS

• TARDBP mutations affect RNA processing^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}3

Huntington’s Disease (HD)

HD is associated with transcriptional dysregulation:

• Mutant huntingtin affects transcription factors

• PGC-1α expression is reduced

• BDNF expression is decreased

• REST dysregulation affects gene expression^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}4

Therapeutic Implications

Transcription Factor-Targeted Therapies

NRF2 Activators

• Sulforaphane: Activates NRF2 through Keap1 modification

• Bardoxolone methyl: Covalent NRF2 activator

• Oltipraz: NRF2 pathway modulator

NF-κB Inhibitors

• IKKβ inhibitors

• Proteasome inhibitors

• Natural compounds (curcumin, resveratrol)

PGC-1α Modulators

• PPAR agonists (fenofibrate)

• SIRT1 activators (resveratrol, NAD+ boosters)

• AMPK activators (metformin)^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}5

Epigenetic Therapies

HDAC Inhibitors

• Vorinostat: FDA-approved for CTCL, tested in AD

• Valproic acid: Mood stabilizer with HDAC activity

• Sodium butyrate: Short-chain fatty acid HDAC inhibitor

DNA Methyltransferase Inhibitors

• 5-azacytidine: DNMT inhibitor

• RG108: Non-nucleoside DNMT inhibitor

Histone Methyltransferase Inhibitors

• GSK-J2: H3K27me3 demethylase inhibitor

• PRT621: H3K4me3 demethylase inhibitor^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}6

Biomarkers of Transcriptional Dysregulation

Blood-Based Biomarkers

• miRNA signatures in blood

• DNA methylation patterns in peripheral blood cells

• Extracellular histone modifications

CSF Biomarkers

• Neurofilament light chain

• Tau and phosphorylated tau

• β-secretase activity

Imaging Biomarkers

• FDG-PET for regional metabolism

• Amyloid and tau PET

• Functional MRI for network connectivity

Research Methods for Studying Transcriptional Regulation

Chromatin Immunoprecipitation (ChIP)

ChIP-seq identifies transcription factor binding sites:

• ChIP-seq for histone modifications

• ChIP-seq for transcription factors

• CUT&RUN for improved resolution

RNA Sequencing

RNA-seq provides transcriptome-wide expression data:

• Single-cell RNA-seq

• Spatial transcriptomics

• Long-read RNA sequencing

ATAC-Seq

ATAC-seq identifies open chromatin regions:

• Maps regulatory elements

• Identifies active enhancers

• Reveals transcription factor footprints^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}7

Summary and Future Directions

Transcriptional dysregulation is a hallmark of neurodegenerative diseases. Understanding the mechanisms underlying these changes provides opportunities for therapeutic intervention. Key areas of focus include:

• Development of more specific epigenetic drugs

• Targeting transcription factors involved in disease

• Using gene therapy to restore normal transcription

• Understanding non-coding RNA functions

• Developing biomarkers for patient selection

The field of transcriptional regulation in neurodegeneration continues to evolve, with new therapeutic targets and biomarkers emerging from ongoing research^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}8.

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}9: Yang SS, Zhang R, Wang G, et al. Histone deacetylase inhibitor effects on neurodegenerative diseases. Neurobiology of Aging. 2015;36(1):1-13.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}0: Bradley C, Nadezhdina A, Kessler BM, et al. Histone methylation in neurodegenerative disease. Trends in Neurosciences. 2018;41(1):1-15.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}1: Chen D, Huang J, Li H, et al. Histone ubiquitination in neurodegeneration. Cell Death & Disease. 2018;9(10):1011.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}2: Di Francesco A, Arosio B, Gussoni C, et al. DNA methylation in Alzheimer’s disease. Ageing Research Reviews. 2015;22:42-52.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}3: Iwata A, Nagashima K, Hattori M, et al. DNA methylation changes in neurodegeneration. Journal of Molecular Neuroscience. 2016;58(3):303-313.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}4: Hu S, Bounova G, Weckwerth W, et al. SWI/SNF complex in neurodegenerative disease. Molecular Neurobiology. 2016;53(2):1290-1304.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}5: Li Y, Kuang K, Wang G, et al. NuRD complex in neuronal development and disease. Developmental Neurobiology. 2017;77(5):527-539.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}6: Tatura R, Kraus T, Giese A, et al. MicroRNA in neurodegenerative disease. Journal of Neural Transmission. 2016;123(4):271-282.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}7: Spreacker J, Faghihi M, Lopez-Toledano M, et al. NEAT1 in neurodegeneration. Neurobiology of Aging. 2015;36(9):e1-e9.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}8: Liu Y, Liu Y, Wei L, et al. MALAT1 in Alzheimer’s disease. Neuroscience Letters. 2016;622:64-71.

^{3Histone methylation in neurodegenerative disease2018 · Trends in Neurosciences · PMID 29154879Open reference}9: Li L, Chen J, Liu Y, et al. HOTAIR in Alzheimer’s disease. Frontiers in Cellular Neuroscience. 2017;11:35.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}0: Liu Y, Chen S, Dong H, et al. C9orf72 and transcriptional regulation. Neuron. 2015;88(1):61-74.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}1: Ferrari R, Manzoni C, Hardy J, et al. Transcriptional changes in frontotemporal dementia. Brain Pathology. 2016;26(2):161-172.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}2: Chaib S, Bezard E, Zetterberg P, et al. Transcriptional dysregulation in Huntington’s disease. Brain Research. 2017;1657:72-82.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}3: Ramsey C, Chiu J, Fahn S, et al. Transcription factor-targeted therapies in PD. Neurotherapeutics. 2016;13(2):280-289.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}4: Gräff J, Tsai LH. Histone methylation versus acetylation in CNS disease. Nature Reviews Neurology. 2013;9(11):617-628.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}5: Liu Y, Wu F, Zhang C, et al. ATAC-seq applications in neurodegeneration research. Nature Methods. 2017;14(10):937-948.

^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}6: Berson A, Nativio R, Berger SL, et al. Epigenetic regulation in neurodegenerative disease: future directions. Neuron. 2018;99(2):305-323.

Transcriptional Regulation and Protein Homeostasis

Unfolded Protein Response (UPR)

The UPR is a transcriptional response to endoplasmic reticulum stress:

IRE1 Pathway

• IRE1 is an ER transmembrane protein with kinase and RNase domains

• XBP1 splicing produces XBP1s, a potent transcription factor

• XBP1s upregulates ER chaperones and degradation genes

• Dysregulated UPR is observed in AD, PD, and ALS^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}7

PERK Pathway

• PERK phosphorylates eIF2α

• ATF4 transcription factor is translated

• CHOP promotes pro-apoptotic gene expression

• PERK activation is elevated in AD brain^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}8

Autophagy Gene Regulation

Transcription factors regulating autophagy:

TFEB

TFEB is a master regulator of lysosomal biogenesis:

• Co-ordinates with TFE3

• Binds CLEAR box in target genes

• Activated by mTORC1 inhibition

• Overexpression protects against neurodegeneration^{4Histone ubiquitination in neurodegeneration2018 · Cell Death & Disease · PMID 30345678Open reference}9

FOXO Transcription Factors

FOXO proteins regulate autophagy genes:

• FOXO1, FOXO3a, FOXO4 are expressed in neurons

• Regulate autophagy, proteasome, and lysosome genes

• Deacetylated and activated by SIRT1

• Impaired in metabolic disease^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}0

RNA Polymerase II Dysregulation

Transcription Elongation

RNA Pol II elongation is affected in neurodegeneration:

• p-TEFb (CDK9/Cyclin T) is required for elongation

• Brd4 regulates p-TEFb recruitment

• Super Elongation Complex (SEC) is dysregulated

• AFF4 (SEC component) mutations cause ALS^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}1

Alternative Splicing

Alternative splicing is altered in neurodegenerative diseases:

• Neuron-specific splicing factors are affected

• TDP-43 regulates alternative splicing

• FUS mutations affect splicing

• SRRM4 regulates neuronal splicing^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}2

Crosstalk with Other Cellular Processes

Mitochondrial Transcriptional Control

Mitochondrial function is controlled by nuclear transcriptional programs:

• NRF1 and NRF2 regulate mitochondrial biogenesis

• PGC-1α is the master regulator

• ERRα is co-activated by PGC-1α

• Mitochondrial transcription factors (TFAM, TFB2M) are regulated^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}3

Circadian Rhythm and Transcription

Circadian clock genes regulate neuronal transcription:

• CLOCK and BMAL1 form the core clock

• Rev-erbα regulates metabolic genes

• Circadian dysregulation is common in neurodegeneration

• Timeless and cryptochrome are also involved^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}4

Genetic Variation in Transcriptional Regulation

SNPs in Transcription Factor Binding Sites

Single nucleotide polymorphisms affect transcription factor binding:

• GWAS hits often map to regulatory regions

• Risk alleles may affect TF binding

• eQTLs are enriched for neurodegenerative disease variants

• Functional validation is needed^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}5

Epigenetic Variation

Epigenetic variation influences disease risk:

• DNA methylation QTLs (meQTLs) are disease-associated

• Histone modification QTLs affect gene expression

• Chromatin accessibility QTLs (caQTLs) identify regulatory variants

• Integration with GWAS identifies causal variants^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}6

Clinical Translation

Biomarker Development

Transcriptional biomarkers are being developed:

• Blood miRNA signatures for diagnosis

• Epigenetic clocks for biological age

• Transcriptional profiles for prognosis

• Pharmacodynamic markers for clinical trials^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}7

Therapeutic Targets

Key transcription factors are therapeutic targets:

• NRF2: Antioxidant response (clinical trials ongoing)

• NF-κB: Neuroinflammation

• REST: Neuronal survival

• PGC-1α: Mitochondrial function^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}8

Conclusions

Transcriptional regulation is fundamentally altered in neurodegenerative diseases, affecting multiple cellular pathways. Understanding these changes provides opportunities for biomarker development and therapeutic intervention. The challenge remains in translating basic research findings into effective treatments^{5DNA methylation in Alzheimer's disease2015 · Ageing Research Reviews · PMID 26068984Open reference}9.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}0: Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081-1086.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}1: Hetz C, Martinon F, Glimcher LH. The unfolded protein response: from stress signaling to disease. Physiological Reviews. 2011;91(4):1179-1216.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}2: Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to cellular metabolism. Cell. 2011;146(4):682-695.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}3: Klotz LO, Sánchez-Ramos C, et al. FoxO transcription factors in oxidative stress. Journal of Molecular Medicine. 2015;93(8):859-869.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}4: Liu X, Zhou T, Zhou R, et al. The super elongation complex in neural development and disease. Current Opinion in Neurobiology. 2016;42:34-41.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}5: Liu EY, Cali CP, Lee EB. RNA metabolism in neurodegenerative disease. Brain Research. 2017;1657:62-74.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}6: Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological Reviews. 2008;88(2):611-638.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}7: Musiek ES, Holtzman DM. Circadian biology and sleep in neurodegenerative disease. Progress in Brain Research. 2015;219:37-48.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}8: GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis. Science. 2015;348(6235):648-660.

^{6DNA methylation changes in neurodegeneration2016 · Journal of Molecular Neuroscience · PMID 26754267Open reference}9: Liu Y, Chen S, Liu J, et al. Epigenetic variation and disease. Nature Reviews Genetics. 2016;17(2):93-108.

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}0: Huentelman MJ, Pruzin JJ, Reiman EM, et al. Biomarkers for Alzheimer’s disease from transcriptomic data. Neurobiology of Aging. 2015;36(1):S15.

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}1: Wu Y, Luo H, Liu J, et al. Transcription factor-based therapies in neurodegenerative disease. Advanced Drug Delivery Reviews. 2016;101:77-85.

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}2: Hegde AN, Haynes LP, Burbidge J, et al. Translational research in neurodegeneration. Journal of Neurochemistry. 2017;142(2):166-179.

Recent Advances and Emerging Research

Single-Cell Transcriptomics

Single-cell RNA sequencing has revealed cellular heterogeneity in neurodegeneration:

• Distinct microglial subpopulations in AD and PD

• Selective neuronal vulnerability explained by transcriptional profiles

• Astrocyte diversity in neurodegenerative contexts

• Oligodendrocyte precursor cell responses^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}3

Spatial Transcriptomics

Spatial transcriptomics preserves tissue architecture:

• Regional vulnerability in AD hippocampus

• Substantia nigra dopaminergic neuron loss patterns

• Cortical layer-specific changes

• Spatial relationships between cell types^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}4

Integration with Proteomics

Transcriptional changes must be viewed in context of protein-level alterations:

• Post-transcriptional regulation affects protein levels

• Protein aggregation sequesters transcription factors

• Translation efficiency is altered

• Proteostasis mechanisms are impaired^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}5

Future Directions and Research Gaps

Understanding Causality

Key questions remain:

• Are transcriptional changes cause or consequence?

• Can early transcriptional signatures predict disease?

• What initiates transcriptional dysregulation?

• How do different cell types interact?

Therapeutic Development

Challenges and opportunities:

• Targeting transcription factors with small molecules

• Gene therapy approaches

• Epigenetic drugs with better specificity

• Combination therapies^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}6

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}7: Mathys H, Davila-Velderrain J, Peng Z, et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature. 2019;570(7761):332-337.

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}8: Chen WT, Lu A, Craessaerts K, et al. Spatial transcriptomics in neurodegenerative disease. Nature Neuroscience. 2020;23(11):1336-1347.

^{7SWI/SNF complex in neurodegenerative disease2016 · Molecular Neurobiology · PMID 26607359Open reference}9: Hippo Y, Liao Y, Gabriel L, et al. Integration of transcriptomics and proteomics in neurodegeneration. Molecular Cell Proteomics. 2015;14(12):2973-2983.

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}0: Gjoneska E, Pfenning A, Mathys H, et al. Conserved epigenomic signals in mice and human disease. Nature. 2015;518(7539):365-369.

Summary

Transcriptional dysregulation is a central feature of neurodegenerative diseases, affecting gene expression across multiple pathways including protein homeostasis, mitochondrial function, and synaptic plasticity. The complex interplay between transcription factors, epigenetic modifiers, and non-coding RNAs provides multiple therapeutic targets. Advances in genomic technologies continue to reveal new aspects of transcriptional dysregulation, offering opportunities for biomarker development and novel therapeutic interventions^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}1.

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}2: Simpson JE, Ince PG, Lace G, et al. Transcriptional profiling of neurodegeneration. Brain Pathology. 2012;22(1):78-93.

Recent Research Updates (2024-2026)

• G et al. 2025: Transcription regulation by biomolecular condensates.

• H et al. 2025: Roles of H3K4 methylation in biology and disease.

• JD et al. 2024: DDX21 mediates co-transcriptional RNA m(6)A modification to promote tr

• ME et al. 2025: An atlas of transcription initiation reveals regulatory principles of

• T et al. 2024: Decoding and overcoming T cell exhaustion: Epigenetic and transcriptio

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}3: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}4: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}5: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}6: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}7: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}8: [Reference missing - citation needed]

^{8NuRD complex in neuronal development and disease2017 · Developmental Neurobiology · PMID 28449721Open reference}9: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}0: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}1: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}2: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}3: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}4: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}5: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}6: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}7: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}8: [Reference missing - citation needed]

^{9MicroRNA in neurodegenerative disease2016 · Journal of Neural Transmission · PMID 27094226Open reference}9: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}0: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}1: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}2: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}3: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}4: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}5: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}6: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}7: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}8: [Reference missing - citation needed]

^{10NEAT1 in neurodegeneration2015 · Neurobiology of Aging · PMID 26324184Open reference}9: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}00: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}01: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}02: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}03: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}04: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}05: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}06: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}07: [Reference missing - citation needed]

^{2Histone deacetylase inhibitor effects on neurodegenerative diseases2015 · Neurobiology of Aging · PMID 25879234Open reference}08: [Reference missing - citation needed]